The impact of molecular ontogeny in AML treated with HMA+VEN is unknown. We found that Secondary ontogeny is selectively responsive to VEN added to HMA and the addition of VEN has no clinical benefit in TP53-mutated AML. rdcu.be/dCCZI Leukemia Journal #amlsm Dana-Farber News

Dr. John Forrest Jr. died last week surrounded by family.

His research focused on pathophysiology & treatment of fluid & electrolyte disorders. Forrest eventually became the only principal investigator in the world to be on five NIH T35 training grants.
medicine.yale.edu/internal-medic…

What is the optimal therapy in molecularly defined secondary AML?
Our multicenter study tries to answer this important question. Pulisehd today in Leukemia. rdcu.be/dy7hW
Thanks to all collaborators and my good friend and mentor Maximilian Stahl

#AMLsm

We are about to start our FREE annual VJHemOnc updates of the #MDSsm highlights from #ASH2023 . Not too late to join. We have 16 talks each 5-min by abstract authors followed by debate/discussion of classification, risk stratification and current/investigational therapies.

Post-ASH 2023 #MDS Highlights: panel discussion on non-disease modifying agents in LR-MDS w/ Amer Zeidan MBBS,MHS ‏عامر زيدان Maximilian Stahl María Díez Campelo Valeria Santini

Join us here: tinyurl.com/yc6zcuvs

We’re hosting a Post-ASH Virtual Highlights Series, featuring presentations & discussions on selected abstracts from #ASH23 , w/ leading #HemOnc experts 💻🩸

Join us for our #MDS session, chaired by Amer Zeidan MBBS,MHS ‏عامر زيدان

Check out the agenda & REGISTER NOW 👉 vjhemonc.com/feature/post-a…

Thank you for the invitation Amer Zeidan MBBS,MHS ‏عامر زيدان and AA&MDSIF. It was great to be back Yale Cancer Center. New Haven and Yale School of Medicine always evoke the best memories for me. Nice to see Amer Zeidan MBBS,MHS ‏عامر زيدان, Nikolai Podoltsev, Mina L Xu and Lourdes Mendez.

Great to see this out! This was my first investigator initiated trial that I wrote during my Oncology fellowship Memorial Sloan Kettering Cancer Center. Thank you Abdel-Wahab Lab for giving me the opportunity to participate in this story.

Looking forward to speaking there about treatment of lower risk MDS

Had a wonderful time talking about the use of venetoclax as part of allogeneic stem cell transplant management in high risk AML at ICBMT. Thank you for the kind invitation to talk about this topic in the beautiful city of Busan.

We are recruiting for next year's (July 2024) ADuong Foley Family Leukemia Fellowship! Join our amazing community. tinyurl.com/3z6a6npn Andy Lane Coleman Lindsley Shai Shimony Lachelle Dawn Chris Reilly Maximilian Stahl Tothova Lab Virginia Volpe, MD and many not on twitter.

Findings from a study indicate that measurable residual disease clearance is associated with favorable outcomes in acute myeloid leukemia following subsequent therapy before allogenic stem cell transplant. #AML | Maximilian Stahl

ow.ly/OR7B50MPR4L